The medical device company is based in Audubon, PA.
"Great margins and cash flow; investments weigh: In our view, GMED will continue to leverage efficient product development to generate portfolio velocity, and its best-in-class margins and cash flow generation to drive further growth," the firm wrote in a note to investors.
Despite this, Barclays believes the company's investments in trauma and robotics will weigh on margins and take time to "bear fruit."
"GMED had slower-than-expected revenue growth in the 1Q16 and we see risk to medium-term numbers. Net-net, we respect the GMED team as operators but anticipate these issues to weigh, driving our EW rating," the firm added.
Shares of Globus Medical are climbing 2.91% to $24.06 late Friday afternoon.
Separately, TheStreet Ratings Team has a "Buy" rating with a score of B on the stock.
The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: GMED